ライフサイエンスコーパス: graft surgery

1 onary angioplasty and coronary artery bypass graft surgery).

2 onary angioplasty and coronary artery bypass graft surgery.

3 n patients undergoing coronary artery bypass graft surgery.

4 4 patients undergoing coronary artery bypass graft surgery.

5 -term mortality after coronary artery bypass graft surgery.

6 2 patients undergoing coronary artery bypass graft surgery.

7 SVG thrombosis after coronary artery bypass graft surgery.

8 8 patients undergoing coronary artery bypass graft surgery.

9 ndergoing nonemergent coronary artery bypass graft surgery.

10 onary intervention or coronary artery bypass graft surgery.

11 ) patients undergoing coronary artery bypass graft surgery.

12 es undergoing primary coronary artery bypass graft surgery.

13 atients who underwent coronary artery bypass graft surgery.

14 es undergoing primary coronary artery bypass graft surgery.

15 n patients undergoing coronary artery bypass graft surgery.

16 infarction following coronary artery bypass graft surgery.

17 previous multi-vessel coronary artery bypass graft surgery.

18 ng and after off-pump coronary artery bypass graft surgery.

19 t-term sedation after coronary artery bypass graft surgery.

20 bidity compared with on-pump coronary bypass graft surgery.

21 nt complication after coronary artery bypass graft surgery.

22 9 patients undergoing coronary artery bypass graft surgery.

23 on complication after coronary artery bypass graft surgery.

24 use of bleeding after coronary artery bypass graft surgery.

25 he need for emergency coronary artery bypass graft surgery.

26 te transfusions after coronary artery bypass graft surgery.

27 .04) transfused after coronary artery bypass graft surgery.

28 g complications after coronary artery bypass graft surgery.

29 to have prior PCI or coronary artery bypass graft surgery.

30 routine partial thickness connective tissue graft surgery.

31 re, and for 5 days following, cardiac bypass graft surgery.

32 en, who had undergone coronary artery bypass graft surgery.

33 c shock, and low-risk coronary artery bypass graft surgery.

34 sites were performing coronary artery bypass graft surgery.

35 pression and previous coronary artery bypass graft surgery.

36 r in combination with coronary artery bypass graft surgery.

37 y syndromes and after coronary artery bypass graft surgery.

38 or patient undergoing coronary artery bypass graft surgery.

39 bleeding unrelated to coronary artery bypass graft surgery.

40 ke when compared with coronary artery bypass graft surgery.

41 isk of mortality with coronary artery bypass graft surgery.

42 neous coronary intervention (PCI) and bypass graft surgery.

43 deemed ineligible for coronary artery bypass graft surgery.

44 re), and a history of coronary artery bypass graft surgery.

45 en, and 30% had prior coronary artery bypass graft surgery.

46 th angiography-guided coronary artery bypass graft surgery.

47 about candidates for coronary artery bypass graft surgery.

48 hythm, and undergoing coronary artery bypass graft surgery.

49 long-term efficacy of coronary artery bypass graft surgery.

50 ntervention, and redo coronary artery bypass graft surgery.

51 g-term outcomes after coronary artery bypass graft surgery.

52 7 patients undergoing coronary artery bypass graft surgery.

53 ons related to trabeculectomy and/or corneal graft surgery.

54 s and were undergoing coronary artery bypass grafting surgery.

55 s undergoing isolated coronary artery bypass grafting surgery.

56 y and mortality after coronary artery bypass grafting surgery.

57 (-0.717; -0.787) and coronary artery bypass graft surgery (-0.541; -0.618).

58 bleeding unrelated to coronary artery bypass graft surgery (1.6% vs 2.3%, RR 0.67, 95% CI 0.49-0.92;

59 or repeat procedures (coronary artery bypass graft surgery: 10.7% versus 6.8%, P=0.04, adjusted hazar

60 .4% vs. 83.7%), prior coronary artery bypass graft surgery (19.8% vs. 61.2%), peripheral vascular dis

61 2.72]; P < .001), and coronary artery bypass graft surgery (3.7% vs 1.3%; AOR, 3.00 [2.63 to 3.41]; P

62 us (45%) and previous coronary artery bypass graft surgery (34%).

63 P < or = 0.001); and coronary-artery bypass graft surgery (35.0 percent vs. 11.1 percent, P < or = 0

64 angioplasty (55%) and coronary artery bypass graft surgery (38%).

65 0.0001) and both post-coronary artery bypass graft surgery (38%, P=0.048) and post-PCI (57%, P<0.0001

66 ial infarction (MI) (45.8%), coronary bypass graft surgery (39.2%), chronic renal failure (18.8%), an

67 curred, including 140 coronary artery bypass graft surgeries (4.1%) and 114 percutaneous coronary int

68 ery (11 patients) and coronary artery bypass graft surgery (4 patients).

69 4), and major bleeding not related to bypass graft surgery (6.9%vs 10.5%, -3.6% [-5.5 to -1.7], 0.64

70 90-day mortality post-coronary artery bypass graft surgery 7% versus 3%, P=0.03; post-PCI 10% versus

71 arget lesion failure (coronary artery bypass graft surgery: 8.9% versus 3.9%, P<0.001, adjusted hazar

72 assignment, and years since coronary bypass graft surgery, a CES-D score > or =16 was positively ass

73 vessel disease, prior coronary artery bypass graft surgery, a history of hypertension, or a recent my

74 n patients undergoing coronary artery bypass graft surgery after 4 wk of consuming a low-GI diet than

75 whites after primary coronary artery bypass graft surgery after adjustment for other covariates (P<0

76 ved satisfaction with coronary artery bypass graft surgery after administration of DEX or propofol fo

77 ity of data comparing coronary artery bypass graft surgery against newer generation stents.

78 of whom 264 underwent coronary artery bypass graft surgery and 487 underwent percutaneous coronary in

79 Guideline Update for Coronary Artery Bypass Graft Surgery and actual clinical practice.

80 Coronary artery bypass graft surgery and angioplasty are two common treatments

81 drug eluting stents, coronary-artery bypass graft surgery and anti-thrombosis.

82 sk of mortality after coronary artery bypass graft surgery and can be used for informed consent and a

83 n-hospital Q-wave MI, coronary artery bypass graft surgery and death were 0.4%, 1.9% and 1.4%, respec

84 rom vein leftovers of coronary artery bypass graft surgery and discarded atrial specimens of transpla

85 atients who underwent coronary artery bypass graft surgery and had an angiogram performed up to 18 mo

86 iaries undergoing any coronary artery bypass graft surgery and higher observed mortality rates (1.7%-

87 VGF is common after coronary artery bypass graft surgery and is associated with repeat revasculariz

88 inical outcomes after coronary artery bypass graft surgery and myocardial infarction in women.

89 multivessel disease, coronary artery bypass graft surgery and percutaneous coronary intervention are

90 ry revascularization (coronary artery bypass graft surgery and percutaneous transluminal coronary ang

91 pt closure, emergency coronary artery bypass graft surgery and restenosis, but do not prevent myocard

92 improvements are the outcome of the initial graft surgery and that the gingivoplasty procedure does

93 cardial infarction or coronary artery bypass graft surgery and those with severe heart failure sympto

94 ctomy, thyroidectomy, coronary artery bypass graft surgery, and carotid endarterectomy.

95 cular surgery, organ transplantation, tissue-graft surgery, and cases managed with low mean arterial

96 rtic aneurysm repair, coronary artery bypass graft surgery, and craniotomy, and for RS of 4 postopera

97 smoking, no previous coronary artery bypass graft surgery, and left anterior descending artery targe

98 ounger age, history of prior coronary bypass graft surgery, and non-white race.

99 yocardial infarction, coronary artery bypass graft surgery, and repeat PCI were primary outcomes comp

100 12 to 18 months after coronary artery bypass graft surgery, and subsequent clinical outcomes.

101 concentrations after coronary artery bypass graft surgery are nearly universally elevated, are deter

102 prediction models for coronary artery bypass grafting surgery are limited to in-hospital or 30-day en

103 onary intervention or coronary artery bypass graft surgery as appropriate) plus GDMT reduces rates of

104 s undergoing elective coronary artery bypass graft surgery at a single tertiary centre could benefit

105 s undergoing isolated coronary artery bypass grafting surgery at 33 medical centers in Michigan betwe

106 f patients undergoing coronary artery bypass grafting surgery at the remaining hospitals and for sele

107 P<0.001); history of coronary artery bypass graft surgery (beta=1.32; CI, 1.28-1.32; P<0.001); 2, 3,

108 re change in rates of coronary artery bypass graft surgery between 2002 to 2003 and 2008 to 2009 amon

109 ing isolated off-pump coronary artery bypass graft surgery between January 2000 and June 2002.

110 nary intervention, or coronary artery bypass graft surgery between January 2000 and September 2007 fr

111 R + CABG) concomitant coronary artery bypass graft surgery between November 10, 1987 through June 30,

112 (VGF) is common after coronary artery bypass graft surgery, but its relationship with long-term clini

113 d be standard care in coronary artery bypass graft surgery, but vein quality and clinical outcomes ha

114 readmission following coronary artery bypass grafting surgery by using nationally representative clin

115 ) (2.3% vs. 3.0%) and coronary artery bypass graft surgery (CABG) (1.3% vs. 1.4%) were similar in wom

116 (PTCA) (n = 834) and coronary artery bypass graft surgery (CABG) (n = 1805) in diabetic patients wit

117 oplasty (PTCA) or for coronary artery bypass graft surgery (CABG) 40 vs. 46%, p = NS).

118 ) with survival after coronary artery bypass graft surgery (CABG) among diabetics in the Veterans Aff

119 atients with previous coronary artery bypass graft surgery (CABG) and acute myocardial infarction (AM

120 elines for the use of coronary artery bypass graft surgery (CABG) and percutaneous coronary intervent

121 rvival and subsequent coronary artery bypass graft surgery (CABG) and percutaneous coronary intervent

122 erum biomarkers after coronary artery bypass graft surgery (CABG) are associated with increased mediu

123 ntervention (PCI) and coronary artery bypass graft surgery (CABG) are being applied to high-risk popu

124 Coronary artery bypass graft surgery (CABG) compared with percutaneous coronary

125 rvival advantage with coronary artery bypass graft surgery (CABG) compared with percutaneous translum

126 ecific causes of post-coronary artery bypass graft surgery (CABG) deaths in the PLATO (Platelet Inhib

127 he need for emergency coronary artery bypass graft surgery (CABG) decreased significantly (p(trend) <

128 h heart failure after coronary artery bypass graft surgery (CABG) has not been examined in a contempo

129 ional risk models for coronary artery bypass graft surgery (CABG) have gained widespread acceptance,

130 ntion (PI) in 30% and coronary artery bypass graft surgery (CABG) in 24%.

131 intervention (PCI) or coronary artery bypass graft surgery (CABG) in physician-directed and patient-c

132 brillation (AF) after coronary artery bypass graft surgery (CABG) is associated with increased morbid

133 Coronary artery bypass graft surgery (CABG) is widely used for the treatment of

134 Patients having coronary artery bypass graft surgery (CABG) may be subject to different care pr

135 lihood of in-hospital coronary artery bypass graft surgery (CABG) might be useful in selecting patien

136 t public reporting of coronary artery bypass graft surgery (CABG) mortality might result in case sele

137 ng minimally invasive coronary artery bypass graft surgery (CABG) on hemodynamic variables and left v

138 who underwent repeat coronary artery bypass graft surgery (CABG) or percutaneous coronary interventi

139 Risks of coronary artery bypass graft surgery (CABG) or percutaneous transluminal corona

140 ta-blocker therapy on coronary artery bypass graft surgery (CABG) outcomes has not been assessed.

141 rative clopidogrel on coronary artery bypass graft surgery (CABG) outcomes.

142 Guidelines recommend coronary artery bypass graft surgery (CABG) over percutaneous coronary interven

143 A major advantage of coronary artery bypass graft surgery (CABG) relative to percutaneous coronary i

144 atients; 312 had only coronary artery bypass graft surgery (CABG) surgery, 37 had both valve and CABG

145 is a complication of coronary artery bypass graft surgery (CABG) that can be difficult to diagnose.

146 quent complication of coronary artery bypass graft surgery (CABG) that leads to increased costs and m

147 onary artery disease, coronary artery bypass graft surgery (CABG) was associated with a lower rate of

148 Diabetes) trial found coronary artery bypass graft surgery (CABG) was associated with better clinical

149 guidelines recommend coronary artery bypass graft surgery (CABG) when treating significant de novo l

150 ized trials comparing coronary artery bypass graft surgery (CABG) with percutaneous coronary interven

151 ized trials comparing coronary artery bypass graft surgery (CABG) with percutaneous transluminal coro

152 troke occurring after coronary artery bypass graft surgery (CABG) without cardiopulmonary bypass (off

153 s complications after coronary artery bypass graft surgery (CABG), and their etiology and implication

154 rse outcomes included coronary artery bypass graft surgery (CABG), myocardial infarction (MI) and dea

155 rse outcomes included coronary artery bypass graft surgery (CABG), myocardial infarction and mortalit

156 angioplasty (PTCA) or coronary artery bypass graft surgery (CABG), should these interventions be need

157 patients treated with coronary artery bypass graft surgery (CABG), we evaluated the impact of providi

158 Non-coronary artery bypass graft surgery (CABG)-related major bleeding within 30 da

159 n patients undergoing coronary artery bypass graft surgery (CABG).

160 intervention (PCI) or coronary artery bypass graft surgery (CABG).

161 a worse outcome after coronary artery bypass graft surgery (CABG).

162 moses during off-pump coronary artery bypass graft surgery (CABG).

163 (AVR) at the time of coronary artery bypass graft surgery (CABG).

164 oplasty compared with coronary artery bypass graft surgery (CABG).

165 ngioplasty (PTCA) and coronary artery bypass graft surgery (CABG).

166 angioplasty (PTCA) or coronary artery bypass graft surgery (CABG).

167 nels as an adjunct to coronary artery bypass graft surgery (CABG).

168 early and late after coronary artery bypass graft surgery (CABG).

169 surgery (MIDCAB) and coronary artery bypass graft surgery (CABG).

170 oplasty (PTCA) versus coronary artery bypass graft surgery (CABG).

171 n and commonly during coronary artery bypass graft surgery (CABG).

172 r operative risk with coronary artery bypass graft surgery (CABG).

173 ve patients underwent coronary artery bypass graft surgery (CABG); all received RA and left internal

174 Patients underwent coronary artery bypass graft surgery (CABG, n=203), percutaneous coronary inter

175 ntion (PCI) and after coronary artery bypass grafting surgery (CABG).

176 rdiopulmonary bypass (coronary artery bypass graft surgery [CABG]) in a broad cross section of U.S. h

177 al revascularization (coronary artery bypass graft surgery [CABG]) versus TAXUS Express (Boston Scien

178 intervention [PCI] vs coronary artery bypass graft surgery [CABG]) were prospectively selected on the

179 angioplasty [PTCA] or coronary artery bypass graft surgery [CABG]), the primary trial end point (coro

180 revascularization, or coronary artery bypass graft surgery--can be selected.

181 patients intended for coronary artery bypass graft surgery compared with the subgroup intended for pe

182 xcluding various post-coronary artery bypass graft surgery complications.

183 na (1.91; 1.59-2.29), coronary artery bypass graft surgery/coronary angioplasty procedure/stent (1.35

184 ly, and 25% underwent coronary artery bypass graft surgery (CTO bypassed in 88%).

185 younger age, previous coronary artery bypass graft surgery, depressive symptoms, and financial diffic

186 Notably, the need for bypass graft surgery due to restenosis is reduced after TAXUS s

187 Coronary artery bypass graft surgery during the index hospitalization, higher m

188 uded death, emergency coronary artery bypass graft surgery (eCABG), non-emergency CABG (non-eCABG), m

189 off-pump and on-pump coronary artery bypass graft surgery for follow-up longer than 5 years is not w

190 t of P4P on access to coronary artery bypass graft surgery for high-risk patients with AMI.

191 had isolated primary coronary artery bypass graft surgery for multivessel coronary artery disease fr

192 e undergoing isolated coronary artery bypass graft surgery from 2004 to 2006.

193 al augmentation procedure (connective tissue graft; surgery group) and an equal number of contralater

194 c shock (n=1705), and coronary artery bypass graft surgery groups.

195 inhibitors (ACEIs) in coronary artery bypass graft surgery has been erratic and controversial.

196 ilure associated with coronary artery bypass graft surgery has significantly increased from 1988 to 2

197 e patients treated by coronary artery bypass graft surgery having at least 1 angiographically interme

198 is recommended after coronary artery bypass graft surgery; however, the consequences of longer wait

199 proves survival after coronary artery bypass graft surgery; however, the survival benefit of multiple

200 ecrosis and Damage in Coronary Artery Bypass Graft Surgery II Trial, a phase 3, multicenter, randomiz

201 t performed 1 or more coronary artery bypass graft surgeries in a given calendar year were classified

202 s undergoing isolated coronary artery bypass graft surgery in 2003.

203 ys and 6 months after coronary artery bypass graft surgery in 229 subjects receiving aspirin monother

204 ardial infarctions or coronary artery bypass graft surgery in 267,427 fee-for-service beneficiaries a

205 first 24 hours after coronary artery bypass graft surgery in 847 consecutive patients.

206 ho underwent isolated coronary artery bypass graft surgery in July through December 2000.

207 syndromes or previous coronary artery bypass graft surgery in periods before (2010 through 2011) and

208 autograft was superior to amniotic membrane graft surgery in reducing the rate of pterygium recurren

209 Screening led to bypass graft surgery in seven patients.

210 lassified as isolated coronary artery bypass grafting surgery in the administrative cohort.

211 atients who underwent coronary artery bypass graft surgery, in whom both prerequisites could be readi

212 nary intervention and coronary artery bypass graft surgery independently contributed to the significa

213 An acute renal event after coronary bypass graft surgery is associated with high mortality and subs

214 ACEI treatment after coronary artery bypass graft surgery is associated with nonfatal in-hospital is

215 logous saphenous vein coronary artery bypass graft surgery is complicated by late graft failure due t

216 ilure associated with coronary artery bypass graft surgery is increasing in the United States.

217 on-pump and off-pump coronary artery bypass graft surgery is not statistically significant.

218 r patients undergoing coronary artery bypass graft surgery is unknown.

219 For coronary artery bypass graft surgery, mortality rates in 1998 to 1999 differed

220 abase associated with coronary artery bypass graft surgery, myocardial infarction/cardiogenic shock,

221 underwent in-hospital coronary artery bypass graft surgery (N = 2,258,711 visits).

222 interval, 0.55-0.67), coronary artery bypass graft surgery (n=1077; hazard ratio, 0.68; 95% confidenc

223 ass index, history of coronary artery bypass graft surgery, number of treated lesions, and chronic to

224 Off-pump coronary artery bypass graft surgery (OPCAB) has been performed for many years,

225 justment for hospital coronary artery bypass graft surgery or cardiac catheterization capability.

226 larization procedure: coronary artery bypass graft surgery or percutaneous coronary intervention (PCI

227 to-expected ratio for coronary artery bypass graft surgery or percutaneous coronary intervention was

228 nd underwent isolated coronary artery bypass graft surgery or percutaneous coronary intervention with

229 on by procedure type (coronary artery bypass graft surgery or percutaneous coronary intervention).

230 of revascularization, coronary artery bypass graft surgery or percutaneous coronary intervention.

231 ortality after either coronary artery bypass graft surgery or percutaneous coronary interventions sep

232 are not suitable for coronary artery bypass graft surgery or percutaneous transluminal coronary angi

233 atients with previous coronary artery bypass graft surgery or presenting with acute ST-segment elevat

234 hout death, emergency coronary artery bypass graft surgery or Q wave myocardial infarction.

235 ronary angioplasty or coronary artery bypass graft surgery or were treated with calcium channel block

236 ood of ACEI/ARB after coronary artery bypass grafting surgery or in patients with renal insufficiency

237 and those undergoing coronary artery bypass graft surgery (OR 0.58; 95% CI 0.55 to 0.60).

238 ivors after surgical (coronary artery bypass graft surgery) or percutaneous (percutaneous coronary in

239 n, emergent or urgent coronary artery bypass graft surgery, or cerebrovascular accident after PCI.

240 rtic aneurysm repair, coronary artery bypass graft surgery, or craniotomy.

241 e death, MI, emergent coronary artery bypass graft surgery, or target lesion revascularization) and A

242 vage fluid rose after coronary artery bypass graft surgery (p < 0.05), but there was no significant c

243 r mortality (58% post-coronary artery bypass graft surgery, P=0.002; 67% post-PCI, P<0.0001).

244 of 47 984 consecutive coronary artery bypass grafting surgeries performed from 1992 to 2014 among 7 m

245 of Thoracic Surgeons coronary artery bypass graft surgery population studied, the median age was 66

246 clinically (previous coronary artery bypass graft surgery prevalence, 48% versus 24%; P<0.001) and a

247 vessel disease, prior coronary artery bypass graft surgery, prior MI, and smoking.

248 patients selected for coronary artery bypass graft surgery, prompt coronary revascularization was ass

249 djusted mortality for coronary artery bypass graft surgery, public reporting on outcomes has expanded

250 al death, in-hospital coronary artery bypass graft surgery, Q wave myocardial infarction) were chosen

251 angiography rates and coronary artery bypass graft surgery rates (R(2)=0.41) with the suggestion of a

252 Coronary artery bypass graft surgery rates for high-risk patients in Premier de

253 Coronary artery bypass graft surgery rates for patients with AMI in Premier dec

254 A coronary artery bypass grafting surgery readmission measure suitable for public

255 clinical outcomes in coronary artery bypass graft surgery remains unclear.

256 onary intervention or coronary artery bypass graft surgery, respectively.

257 al year 2003 isolated coronary artery bypass grafting surgery results based on an audited and validat

258 ization among the 381 coronary artery bypass graft surgery-selected patients in the highest angiograp

259 a strategy of prompt coronary artery bypass graft surgery significantly reduces the rate of death/my

260 rmed angina pectoris, coronary artery bypass graft surgery, stents, and angioplasty.

261 isk groups within the coronary artery bypass graft surgery stratum, or in any subgroups within the pe

262 coronary angioplasty, coronary artery bypass graft surgery, stroke).

263 l infarction, angina, coronary artery bypass graft surgery, stroke, claudication, gangrene, or tissue

264 s vein grafts used in coronary artery bypass graft surgery suffer from lower patency rates compared t

265 Use is higher after coronary artery bypass graft surgery than with acute myocardial infarctions not

266 major complication of coronary artery bypass graft surgery that is strongly associated with in-hospit

267 ary syndrome/no prior coronary artery bypass graft surgery that were rated as inappropriate decreased

268 For coronary artery bypass graft surgery, the relationship is modest, and there app

269 of TMR combined with coronary artery bypass graft surgery (TMR + CABG) versus bypass alone in patien

270 d patients with a history of coronary bypass graft surgery to either an aggressive or a moderate lipi

271 s undergoing off-pump coronary artery bypass graft surgery using a large patient sample and a risk-ad

272 nonemergent, isolated coronary artery bypass grafting surgery using cardiopulmonary bypass by 32 surg

273 disparity in isolated coronary artery bypass grafting surgery volume (4440 clinical, 5657 administrat

274 unction who underwent coronary artery bypass graft surgery was 19.8%.

275 Performance of coronary artery bypass graft surgery was also associated with a lower recurrent

276 FFR-guided coronary artery bypass graft surgery was associated with a lower number of graf

277 infarction following coronary artery bypass graft surgery was associated with a significant increase

278 reported that EVH for coronary artery bypass graft surgery was associated with worse outcomes than wi

279 In 429 patients, coronary artery bypass graft surgery was based solely on angiography (angiograp

280 Simultaneous coronary artery bypass graft surgery was performed in 32 patients (62%).

281 Coronary artery bypass graft surgery was the only significant predictor of late

282 g not associated with coronary artery bypass graft surgery were also increased among patients with IP

283 artery (IMA) of 7 patients undergoing bypass graft surgery were assessed for IL-8 content by specific

284 Admissions after coronary artery bypass graft surgery were excluded.

285 MIs related to coronary artery bypass graft surgery were few, but numerical excess was observe

286 ted intraocular pressure (IOP) after corneal graft surgery were included.

287 s undergoing elective coronary artery bypass graft surgery were randomized to atorvastatin 40 mg/d or

288 on and indication for coronary artery bypass graft surgery were randomized to botulinum toxin (Xeomin

289 y patients undergoing coronary artery bypass graft surgery were randomized to RIPC (n=30) or control

290 s undergoing elective coronary artery bypass graft surgery were randomly assigned to either a remote

291 nterventions, such as coronary artery bypass graft surgery, were also included, totaling 362 patients

292 that patients having coronary artery bypass graft surgeries with an internal mammary artery (IMA) ha

293 ents before and after coronary artery bypass graft surgery with cardiopulmonary bypass and lobectomy.

294 tudy of 4801 patients having coronary bypass graft surgery with cardiopulmonary bypass from November

295 oing primary elective coronary artery bypass graft surgery with cardiopulmonary bypass to determine w

296 n patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass, increased atr

297 al stunning following coronary artery bypass graft surgery with cardiopulmonary bypass, it reduced ca

298 derwent jugular-carotid interposition bypass graft surgery with intraoperative adenoviral gene transf

299 s undergoing isolated coronary artery bypass graft surgery with LIMA to left anterior descending arte

300 tudy population, 1482 coronary artery bypass grafting surgeries with BIMA were identified, and 1297 p